David Fajgenbaum
David Fajgenbaum is a physician and professor of translational medicine and human genetics at the University of Pennsylvania. His published research primarily focuses on the pathophysiology, diagnosis, and treatment of Castleman disease, including idiopathic multicentric Castleman disease and related syndromes. Additionally, his work investigates drug repurposing methodologies and computational pharmacophenomics to identify new uses for approved medications.
Fact-checked episodes
Publications
- Expert Perspective: Diagnosis and Treatment of Castleman Disease.
- Distinct interleukin-6 production in IPL and TAFRO subtypes of idiopathic multicentric Castleman disease.
- Medicines, Diseases, Indications, and Contraindications (MeDIC): a foundational resource to support drug repurposing.
- How I diagnose Castleman disease.
- Quantify unmet medical need across the disease landscape - A large language model-based methodology.
- Breast-implant associated unicentric castleman disease: a case report.
- Lenalidomide-Dexamethasone as an Effective and Well-Tolerated Treatment Option for Refractory Rosai-Dorfman-Destombes Disease: A Clinical and Pharmacophenomic Study.
- Correction: Quantify unmet medical need across the disease landscape - A large language model-based methodology.
- Characterization of the genotypic and phenotypic spectrum of TCF7L2-related neurodevelopmental disorder (TRND).
- Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study.
- Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.
- No evidence for active viral infection in unicentric and idiopathic multicentric Castleman disease by Viral-Track analysis.
- Exploring the Clinical Diversity of Castleman Disease and TAFRO Syndrome: A Japanese Multicenter Study on Lymph Node Distribution Patterns.
- Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman's Disease.
- Pioneering a new field of computational pharmacophenomics to unlock the life-saving potential of existing medicines.
- Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.
- Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.
- The Involvement of PI3K-Akt Signaling in the Clinical and Pathological Findings of Idiopathic Multicentric Castleman Disease-Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis, and Organomegaly and Not Otherwise Specified Subtypes.
- Erratum to: Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
- Rare Disease Drug Repurposing.
- International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis.
- Interferon-γ sparks inflammatory fire in Castleman disease.
- A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model.
- Ferritin, C-Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH.
- Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.
- Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
- Lymphadenopathy in the rheumatology practice: a pragmatic approach.
- Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
- Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
- Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
- Insights into the etiology of Castleman disease.
- Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO.
- CRP and sCD25 help distinguish between adult-onset Still's disease and HLH.
- The clinical picture of Castleman disease: a systematic review and meta-analysis.
- Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination.
- The Cytokine Storm of Multicentric Castleman Disease.
- Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.
- Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy.
- The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease.
- Refractory idiopathic multicentric Castleman disease responsive to sirolimus therapy.
- Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis.
- Correction to: Sharing is caring: a call for a new era of rare disease research and development.
- A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease.
- A model for crowdsourcing high-impact research questions for Castleman disease and other rare diseases.
- A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
- A novel cryopreservation and biobanking strategy to study lymphoid tissue stromal cells in human disease.
- Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
- Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
- Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy.
- Transcriptome and unique cytokine microenvironment of Castleman disease.
- A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD.
- Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
- Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
- The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
- Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass.
- Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis.
- Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
- Thrombocytopenia, anasarca, and severe inflammation.
- Anti-type I interferon antibodies as a cause of severe COVID-19.
- Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
- Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply.
- Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.
- How we manage idiopathic multicentric Castleman disease.
- Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis.
- Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.
- Sharing is caring: a call for a new era of rare disease research and development.
- CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
- HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease.
- Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply.
- UCD with MCD-like inflammatory state: surgical excision is highly effective.
- Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
- Cytokine Storm. Reply.
- Adrenalitis and anasarca in idiopathic multicentric Castleman's disease.
- DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells.
- Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate.
- Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
- Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease.
- Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
- TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
- Castleman disease.
- AA amyloidosis associated with Castleman disease: A case report and review of the literature.
- Genetic basis for iMCD-TAFRO.
- Overview of Castleman disease.
- Increased mTOR activation in idiopathic multicentric Castleman disease.
- Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
- Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.
- Teaching Old Drugs New Tricks: Statins for COVID-19?
- Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
- Commentary on A Case of Rapid Deterioration with Marked Hypergammaglobulinemia.
- Cytokine Storm.
- International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
- Symptomatic relapse and long-term sequelae of COVID-19 in a previously healthy 30-year-old man.
- ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
- Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
- Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
- Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'.
- Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
- Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.
- Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
- Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
- The Collaborative Network Approach: a model for advancing patient-centric research for Castleman disease and other rare diseases.
- The full spectrum of Castleman disease: 273 patients studied over 20 years.
- Castleman Disease Pathogenesis.
- Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
- Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
- Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
- International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
- A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease.
- Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference.
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
- Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
- Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome.
- International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
- Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
- TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
- TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature.
- Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
- Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
- The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research.
- Idiopathic multicentric Castleman's disease: a systematic literature review.